Molnupiravir Use Among Patients with COVID-19 in Real-World Settings: A Systematic Literature Review.

Julia Richmond DiBelloValerie T Raziano Xinyue LiuAmy PuenpatomKathryn Peebles Nazleen F KhanDeanna D Hill

Published in: Infectious diseases and therapy (2024)

In this SLR study, treatment with MOV was effective in reducing the risk of severe outcomes from COVID-19 caused by Omicron variants, especially for older individuals. Differences in the ages and baseline comorbidities of the MOV-treated and control groups may have led to underestimation of the effectiveness of MOV in many observational studies. Real-world studies published to date thus provide additional evidence supporting the continued benefits of MOV in non-hospitalized adults with COVID-19.

Keyphrases

coronavirus disease
sars cov
randomized controlled trial
systematic review
copy number
respiratory syndrome coronavirus
early onset
gene expression
community dwelling
drug induced
newly diagnosed
light emitting